Collaborate or Stagnate
Can pharma get over its IP anxiety and embrace meaningful partnerships?
Charlotte Barker |
Collaboration within companies is clearly vital, and these days big pharma working with biotechs is a given. Pharma companies have a long history of partnering with academia too – on page 10, University of California professor Greg Weiss reports that he has already had a number of calls from companies wanting to explore the exciting technology he has developed.
Unsurprisingly, collaboration between rival companies is much less common. However, in “Meet The Green Team”, green chemistry consultant Andy Wells draws attention to the “remarkable” increase in pre-competitive industry collaboration over the past 10 years. Why? To find leaner, greener manufacturing strategies. As well as joining forces on sustainability initiatives, companies have been collaborating on large-scale R&D projects (1) and working together to help develop new licensing pathways (2).
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine